Gastrointestinal Cancer

The FDA approval of dabrafenib plus trametinib for BRAF V600E–mutated unresectable or metastatic solid tumors highlights a potential need for routine BRAF testing in clinical practice, experts say.

Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership.

Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.

Ken Kato, MD, PhD, a medical oncologist at the National Cancer Center of Tokyo, and investigator in the pivotal CheckMate 648 study, underscores relevant safety data updates from the trial and important symptom management considerations with the FDA-approved combinations.

At data cutoff, all treated patients in a phase 2 trial experienced a clinical complete response with single-agent dostarlimab-gxly.

Panitumumab with mFOLFOX demonstrated a clinical benefit for patients with left-sided RAS wild-type metastatic colorectal cancer in the PARADIGM trial (NCT02394795).

Patients with KRAS wild-type pancreatic cancer elicited a significant survival benefit with the addition of nimotuzumab to gemcitabine vs placebo plus gemcitabine in a phase 3 trial.

Kellie Zeichner, RN, BSN, OCN, discusses the production of biosimilars, their approval and naming processes, and why immunogenicity is important when discussing these agents.

Nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab received FDA approval as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status

Strategies to combat ethnic disparities in colorectal cancer screening are not limited to the clinic.

Patients with clear cell renal cell carcinoma experienced reduced levels of hypoxia inducible factor-2 alpha expression following treatment with ARO-HIF2.

Laura Zitella, MS, RN, ACNP-BC, AOCN, reviews a case study where a 52-year-old female patient with metastatic colorectal carcinoma begins experiencing diffuse abdominal pain.

Adding the immunotherapy to chemotherapy in the frontline setting may improve overall survival for patients with advanced biliary tract cancer.

Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.

A long-term analysis of the phase 3 BILCAP study highlighted modest benefit for patients with resected biliary tract cancer who received capecitabine following surgery.

TTX-030 is the first fully human IgG4 antibody designed to target CD39, as well as the first CD39 inhibitor to undergo a phase 1 clinical trial.

The addition of temozolomide to a low-dose treatment plan of ipilimumab and nivolumab extended progression-free survival among patients with metastatic colorectal cancer.

Patients with metastatic renal cell carcinoma have multiple effective frontline treatment options.

Cabozantinib plus atezolizumab did not outperform sorafenib in improving overall survival in advanced hepatocellular carcinoma.

Investigators are looking to evaluate whether immunotherapy in the frontline setting, with or without chemotherapy, might improve prognoses for advanced esophageal squamous cell carcinoma.

Patients with treatment-naïve advanced gastrointestinal stromal tumors demonstrated promising responses following treatment with the TKI imatinib plus the MEK inhibitor binimetinib.

The oral targeted therapy was linked with maintained appetite, eating habits, and physical function in patients with IDH1-mutated cholangiocarcinoma.

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.

Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.

In a 12-month follow-up, the experimental regimen continued to provide clinical benefit to patients with esophageal cancer without compromising quality of life or exhibiting an unmanageable safety profile.